Successful pancreatectomy after conversion-intended chemotherapy using gemcitabine and nab-paclitaxel for unresectable adenosquamous carcinoma of the pancreas: a case report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Successful pancreatectomy after conversion-intended chemotherapy using gemcitabine and nab-paclitaxel for unresectable adenosquamous carcinoma of the pancreas: a case report ; volume:10 ; number:1 ; day:16 ; month:8 ; year:2024 ; pages:1-9 ; date:12.2024
Surgical case reports ; 10, Heft 1 (16.8.2024), 1-9, 12.2024
- Creator
-
Nakamura, Kenichi
Nakagawa, Mitsuru
Ariga, Mizuki
Higashiguchi, Takahiko
Chikaishi, Yuko
Matsuo, Kazuhiro
Nishijima, Aki
Endo, Tomoyoshi
Kikuchi, Kenji
Morohara, Koji
Katsuno, Hidetoshi
Tachi, Yoshihiko
Uyama, Ichiro
Suda, Koichi
Morise, Zenichi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40792-024-01989-5
- URN
-
urn:nbn:de:101:1-2411032133504.790982008387
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nakamura, Kenichi
- Nakagawa, Mitsuru
- Ariga, Mizuki
- Higashiguchi, Takahiko
- Chikaishi, Yuko
- Matsuo, Kazuhiro
- Nishijima, Aki
- Endo, Tomoyoshi
- Kikuchi, Kenji
- Morohara, Koji
- Katsuno, Hidetoshi
- Tachi, Yoshihiko
- Uyama, Ichiro
- Suda, Koichi
- Morise, Zenichi
- SpringerLink (Online service)
Other Objects (12)
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Pankreaskarzinom nab-Paclitaxel
Breast cancer nab-Paclitaxel
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer
Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Pankreaskarzinom nab-Paclitaxel
Breast cancer nab-Paclitaxel
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer
Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Pankreaskarzinom nab-Paclitaxel
Breast cancer nab-Paclitaxel
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer
Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial